Viral safety of a pasteurized, monoclonal antibody-purified factor VIII concentrate in previously untreated haemophilia A patients

Haemophilia

Volumn 7, Issue 2, 2001, Pages 146-153

  Philipp, C S ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Haemophilia A; Immunoaffinity purified FVIII; Monoclate P; Pasteurized; Previously untreated patients; Viral safety

Indexed keywords

ALANINE AMINOTRANSFERASE; BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 8 INHIBITOR; HEPATITIS A ANTIBODY; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; MONOCLONAL ANTIBODY; OCTAVI FACTOR VIII; THROMBIN;

ADOLESCENT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG PURIFICATION; DRUG SAFETY; FEVER; HEMOPHILIA A; HEPATITIS A; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOAFFINITY CHROMATOGRAPHY; INFANT; INFECTION; MALE; MEDICAL ASSESSMENT; MULTICENTER STUDY; NEWBORN; OTITIS MEDIA; PASTEURIZATION; PHARYNGITIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY CONTROL; RASH; SCREENING; VIRUS INACTIVATION;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; CHILD; CHILD, PRESCHOOL; CONSUMER PRODUCT SAFETY; FACTOR VIII; HEMOPHILIA A; HUMANS; INFANT; INFANT, NEWBORN; ISOANTIBODIES; MALE; PROSPECTIVE STUDIES; STERILIZATION;

EID: 0035085357     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2516.2001.00482.x     Document Type: Article

References (25)

1. Viral safety of a new highly purified factor VIII
2. Elimination of non-lipid enveloped viruses in the preparation of a monoclonal antibody purified and pasteurized factor VIII concentrate (Monoclate-P®)
3. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs
4. Non-A non-B hepatitis after transfusion of factor VIII in infrequently treated patients
5. Characterization of the human factor VIII procoagulant protein with a heterologous precipitating antibody
6. A prospective study of human immunodeficiency virus type 1 infection and the development of AIDS in subjects with hemophilia
7. The changing prognosis of classic hemophilia (factor VIII 'deficiency')
8. High risk of non-A non-B hepatitis after a first exposure to volunteer or commercial clotting factor concentrates: Effects of prophylactic immune serum globulin
9. Epidemiology of inhibitors in haemophilia A
10. Viral safety and inhibitor development associated with factor VIII:C ultra-purified from plasma in hemophiliacs previously unexposed to factor VIII:C concentrates
11. Outbreak of hepatitis A among Italian patients with haemophilia
12. Revision of the protocol recommended for studies of safety from hepatitis of clotting factor concentrates
13. Inactivation of hepatitis A virus by heat treatment in aqueous solution
14. Virus safety of human immunoglobulins: Efficient inactivation of hepatitis C and other human pathogenic viruses by the manufacturing procedure
15. Inactivation of HIV, HBV, HCV related viruses and other viruses in human plasma derivatives by pasteurization
16. Factor VIII inhibitors in previously treated haemophilia A patients with a double virus-inactivated plasma derived factor VIII concentrate
17. A higher than expected incidence of factor VIII inhibitors in multitransfused haemophilia A patients treated with an intermediate purity pasteurized factor VIII concentrate
18. Removal of viral contaminants by monoclonal antibody purification of plasma proteins
19. The preclinical characterization of monoclate factor VIII:C antihemophilic factor (human)
20. Haemophilia A mutation type determines risk of inhibitor formation
21. Incidence of inhibitors in patients with severe and moderate hemophilia A treated with factor VIII concentrates
22. Hepatitis A virus infections associated with clotting factor concentrate in the United States
23. Validation of a PCR assay system to screen plasma for HBV, HCV, and HIV-1
24. Nonresponse to hepatitis B vaccines and the kinetics of anti-HBs production